Antimicrobial Susceptibility Profile of Contemporary Clinical Strains ofStenotrophomonas maltophiliaIsolates: Can Moxifloxacin Activity Be Predicted by Levofloxacin MIC Results?

Abstract

The susceptibility profile of 763 Stenotrophomonas maltophilia isolates was evaluated against 16 antimicrobials by the CLSI reference broth microdilution method. Minocycline (MIC(90), 1 microg/ml; 100.0% susceptible) was the most active compound, followed by doxycycline (MIC(90), 4 microg/ml; 99.6% susceptible), trimethoprim/sulfamethoxazole (MIC(90), 1 microg/ml; 97.8% susceptible), and tigecycline (MIC(90), 2 microg/ml). An excellent correlation between levofloxacin (MIC(90), 4 microg/ml; 86.5% susceptible by published breakpoint criteria) and moxifloxacin (MIC(90), 2 micro g/ml) MIC results was observed indicating that moxifloxacin could be further evaluated as a therapeutic option for S. maltophilia infections.

Antimicrobial Susceptibility ofStenotrophomonas maltophiliaIsolates from a Korean Tertiary Care Hospital

“…No isolates were resistant to minocycline. This data was similar to that of Taiwan, Brazil, Spain, and the USA 5,15-17. MICs of tigecycline ranged from 0.25 to 8 µg/mL, and MIC 50 and MIC 90 were 1 and 2 µg/mL, respectively, which were similar to those in other studies 1,11.…”

A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused byStenotrophomonas maltophilia

“…Levofloxacin and moxifloxacin have good in vitro activity against S. maltophilia, especially moxifloxacin, which has lower MIC values against S. maltophilia than earlier quinolones [35]. In the present study, although the susceptibility rates were a little lower than some previous studies [1], these two drugs demonstrated good in vitro activity.…”

Current Situation of Antimicrobial Resistance and Genetic Differences inStenotrophomonas maltophiliaComplex Isolates by Multilocus Variable Number of Tandem Repeat Analysis

“…The tetracycline derivatives minocycline and tigecycline have shown good in vitro activity against clinical isolates of S. maltophilia [3]. Previous studies in Taiwan, Brazil, Spain, and the USA showed that there was no or low resistance to tigecycline [3202122]. However, this study showed that 11.9% of clinical 118 S. maltophilia complex isolates displayed resistance to tigecycline.…”

“…This rate was much higher than the rate in previous studies, although the patient group in this study did not include patients with cystic fibrosis who usually show high resistance rates to TMP/SMX according to previous studies. The resistance rate to levofloxacine was 30.5%, which was higher than the rates of 3 to 13% seen in a previous studies [3121314202122]. The tetracycline derivatives minocycline and tigecycline have shown good in vitro activity against clinical isolates of S. maltophilia [3].…”